These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37417744)

  • 21. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
    Nishtala PS; Gill S; Chyou TY
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1689-1695. PubMed ID: 33078448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database.
    Li H; Zhang M; Jiao X; Zhu Y; Liu Y; Zeng L; Wang H; Zhang L; Zhang W; Zhang L
    Sci Rep; 2023 Mar; 13(1):4475. PubMed ID: 36934109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
    Battini V; Carnovale C; Clementi E; Sessa M
    Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
    Nicholls C; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
    Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
    Wen H; Lu C; Zhang M; Qi X
    Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety profile of carbapenems: Data mining of the FDA adverse events reporting system.
    Ge W; Hu H; Li C; Wang L; Xia J
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):594-602. PubMed ID: 33896448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
    Shu Y; Wang L; Ding Y; Zhang Q
    Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
    Sakaeda T; Kadoyama K; Minami K; Okuno Y
    Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
    Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
    Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.